2020 review: unlocking the value of health data

doc.ai was founded with the bold mission of unlocking the value of real world data from research to care. We’ve worked on breaking down data silos in healthcare ultimately increasing the pace of innovation and creating pathways to better health outcomes.

Simultaneously, we’ve worked to help retain the privacy and security of the most sensitive information - health data.

Our enterprise AI offerings – both product and platform solutions – are deployed on cloud-agnostic, zero-trust infrastructure that enables our customers to launch products securely, faster, and at lower cost. For example this year, Anthem, Inc., extended our partnership to continue their digital-first focus over the next five years.

As we head into the holidays and new year, we’re taking a moment to reflect on all that our team has accomplished.

Accelerating health research

While more than 500 companies have publicly noted disruptions or delays with their clinical trials, many are opting for hybrid or decentralized clinical trials. New digital technologies in trials allow rich, remote, and real-time data gathering (all from a participants home) via smart devices. Since 2018, doc.ai has been at the forefront of smartphone-based digital health studies where participant engagement and privacy are at the core.

Here’s a quick look at three of the digital health studies we launched in 2020:

  • Usability study of at-home COVID-19 blood tests - When COVID-19 hit, Vessel Health wanted to better understand the human factors and the usability of their at-home COVID-19 blood test. In a matter of a few weeks, doc.ai created all the study’s requirements including protocols, survey questions, e-consent, telehealth connections, and antibody test shipping integration, and deployed and IRB-approved study to support Vessel Health’s journey to FDA approval. The surveys and protocols were designed in partnership with Vessel Health to meet stringent FDA standards.
  • Biometric markers for myasthenia gravis - doc.ai and UCB biopharma are leveraging state-of-the-art tech to detect and predict myasthenia gravis symptom patterns. This Real World Data study uses smartphones to detect voice and facial patterns of people with myasthenia gravis to build an AI model to correlate biomarker signatures with clinical symptoms. Such advancements are likely to help researchers worldwide better understand this complex disease and develop improved treatments.
  • Remote study for congestive heart failure (CHF) - This study evaluates how remote sensors can help monitor congestive heart failure (CHF), which affects more than 5.7 million people in the US, with a cost to the healthcare system that is projected to reach $69.8 billion by 2030. Early detection of worsening CHF is critical for targeting preventive and therapeutic interventions. Home-based sensors have the potential to catch issues earlier, intervene, and help treat and keep patients at home rather than require an expensive emergency room visit or hospital stay.

Bringing health safety to the workplace

This year has forced everyone to think about the health and safety of their families, friends, neighbors, and co-workers. Business leaders needed customizable solutions that protect employees in their return to work. We quickly responded by launching Passport, our COVID-19 evaluation tool for a safer re-entry to the workplace. Passport uses a privacy-first approach with edge AI technology. This means data entered into Passport never leaves employees’ phones - employers simply have access to whether or not the employee is eligible for going back to the office. Today, Passport is used in 800+ locations around the US across multiple sectors including financial institutions, hotels and hospitality, entertainment, schools and construction companies.

Modernizing behavioral & mental health

The pandemic offers new opportunities as we head into 2021 to accelerate the adoption and use of digital healthcare tools and virtual care. In doing so, we can significantly improve the long-standing problem of inadequate access to mental health services and more effectively meet mental health needs.

This is why we’ve developed Serenity Clinical Builder, a solution to empower clinicians, researchers, and telehealth providers to build and deploy clinical protocols and care materials with ease and at scale.

Customers and consortiums

As part of our response to the COVID-19 pandemic, we’re collaborating with the Roche data science research consortium and the Linux Foundation Public Health consortium, and participating in developing data pipelines to help major healthcare systems build up their recovery resource networks.

Our experience and leadership in decentralized clinical trials led my co-founder and Chief Scientific Officer at doc.ai, Walter De Brouwer, to be invited as Chair of the IEEE Committee for technology and data harmonization to enable decentralized clinical trials with Synthetic Arms and Federated Learning.

Finally, none of this would be possible without our fantastic team of brilliant minds. We expanded our fully-remote team from 50 to 70 people and welcomed Nirav R. Shah, MD, MPH as our Chief Medical Officer.

As we move forward into 2021, doc.ai is ready to scale the deployment of decentralized clinical trials and clinical care materials with more customers to improve the health of millions of people. Our unified machine learning platform is also ready to handle that scale, building and training the algorithms of our health.

This year was an unprecedented year of disruption in science and healthcare, and we are humbled by the opportunities lying ahead of us.

Thank you to all of our customers, partners, and the entire community for your trust in our team and for supporting our vision.